Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Pediatr Nephrol ; 33(11): 2057-2071, 2018 11.
Article in English | MEDLINE | ID: mdl-29372302

ABSTRACT

Hemolytic uremic syndrome (HUS) is defined as a triad of noninmune microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. The most frequent presentation is secondary to Shiga toxin (Stx)-producing Escherichia coli (STEC) infections, which is termed postdiarrheal, epidemiologic or Stx-HUS, considering that Stx is the necessary etiological factor. After ingestion, STEC colonize the intestine and produce Stx, which translocates across the intestinal epithelium. Once Stx enters the bloodstream, it interacts with renal endothelial and epithelial cells, and leukocytes. This review summarizes the current evidence about the involvement of inflammatory components as central pathogenic factors that could determine outcome of STEC infections. Intestinal inflammation may favor epithelial leakage and subsequent passage of Stx to the systemic circulation. Vascular damage triggered by Stx promotes not only release of thrombin and increased fibrin concentration but also production of cytokines and chemokines by endothelial cells. Recent evidence from animal models and patients strongly indicate that several immune cells types may participate in HUS physiopathology: neutrophils, through release of proteases and reactive oxygen species (ROS); monocytes/macrophages through secretion of cytokines and chemokines. In addition, high levels of Bb factor and soluble C5b-9 (sC5b-9) in plasma as well as complement factors adhered to platelet-leukocyte complexes, microparticles and microvesicles, suggest activation of the alternative pathway of complement. Thus, acute immune response secondary to STEC infection, the Stx stimulatory effect on different immune cells, and inflammatory stimulus secondary to endothelial damage all together converge to define a strong inflammatory status that worsens Stx toxicity and disease.


Subject(s)
Escherichia coli Infections/immunology , Hemolytic-Uremic Syndrome/immunology , Microvessels/pathology , Shiga-Toxigenic Escherichia coli/immunology , Animals , Complement Pathway, Alternative/immunology , Cytokines/immunology , Cytokines/metabolism , Disease Models, Animal , Endothelial Cells/immunology , Endothelial Cells/pathology , Endothelium, Vascular/cytology , Endothelium, Vascular/immunology , Endothelium, Vascular/pathology , Epithelial Cells/immunology , Epithelial Cells/pathology , Escherichia coli Infections/blood , Escherichia coli Infections/microbiology , Escherichia coli Infections/pathology , Hemolytic-Uremic Syndrome/blood , Hemolytic-Uremic Syndrome/microbiology , Hemolytic-Uremic Syndrome/pathology , Humans , Intestinal Mucosa/microbiology , Kidney/blood supply , Kidney/immunology , Kidney/pathology , Microvessels/cytology , Microvessels/immunology , Shiga-Toxigenic Escherichia coli/isolation & purification
2.
J Innate Immun ; 8(4): 400-11, 2016.
Article in English | MEDLINE | ID: mdl-27230920

ABSTRACT

Hemolytic uremic syndrome (HUS), a vascular disease characterized by hemolytic anemia, thrombocytopenia, and acute renal failure, is caused by enterohemorrhagic Shiga toxin (Stx)-producing bacteria, which mainly affect children. Besides Stx, the inflammatory response mediated by neutrophils (PMN) is essential to HUS evolution. PMN can release neutrophil extracellular traps (NET) composed of DNA, histones, and other proteins. Since NET are involved in infectious and inflammatory diseases, the aim of this work was to investigate the contribution of NET to HUS. Plasma from HUS patients contained increased levels of circulating free-DNA and nucleosomes in comparison to plasma from healthy children. Neutrophils from HUS patients exhibited a greater capacity to undergo spontaneous NETosis. NET activated human glomerular endothelial cells, stimulating secretion of the proinflammatory cytokines IL-6 and IL-8. Stx induced PMN activation as judged by its ability to trigger reactive oxygen species production, increase CD11b and CD66b expression, and induce NETosis in PMN from healthy donors. During HUS, NET can contribute to the inflammatory response and thrombosis in the microvasculature and thus to renal failure. Intervention strategies to inhibit inflammatory mechanisms mediated by PMN, such as NETosis, could have a potential therapeutic impact towards amelioration of the severity of HUS.


Subject(s)
Bacterial Infections/immunology , Endothelial Cells/immunology , Extracellular Traps/immunology , Hemolytic-Uremic Syndrome/immunology , Kidney/pathology , Neutrophils/immunology , Shiga Toxin/immunology , Acute Kidney Injury , Anemia, Hemolytic , Apoptosis , Cells, Cultured , Child , Humans , Interleukin-6/metabolism , Interleukin-8/metabolism , Neutrophil Activation , Neutrophils/microbiology , Reactive Oxygen Species/metabolism , Thrombocytopenia
SELECTION OF CITATIONS
SEARCH DETAIL
...